KRAS and metastatic neoplasm: Importantly, in metastatic tumors, loss of LKB1 protein expression was found to correlate significantly with concurrent loss of STING, (p = 0.014) and p-AMPK expression; with KRAS mutations, 39% (13/147 vs. 19/147); with KC status, 29% (12/41), (p < 0.001); with low levels of LKB1 RNA (p = 0.008); and with high CD24 expression (p = 0.025).